glp-1 reconstitution calculator Peptide Journal Log – Tracker Form Printable + BONUS Peptide Peptide Calculator | Honest Peptide

Carpal tunnel-style symptoms, including tingling or numbness in the hands, are commonly interpreted as a sign of excessive GH/IGF-1 exposure in community protocols, prompting a dose reduction or pause consult a clinician

Chew well before swallowing

PPMS Phase 3 initiation expected 2026)North AmericaEurope IMU-856IMU-856 / SIRT6 modulator / Oral small molecule / Gastrointestinal diseasesCeliac diseasePhase 1bCompleted (positive proof-of-concept)Global IMU-381IMU-381 / Nurr1 / Oral small molecule / Autoimmune diseasesNeurologic, gastrointestinal and other autoimmune diseasesPreclinicalPreclinical 3assets 3assets RilonaceptARCALYST 3assets tarcocimab tedromerZenkuda / VEGF / Antibody Biopolymer Conjugate (ABC) / OphthalmologyWet Age-Related Macular Degeneration (wet AMD)Diabetic RetinopathyRetinal Vein Occlusion (RVO) KSI-501KSI-501 / IL-6 / VEGF / Bispecific Antibody Biopolymer Conjugate (ABC) / OphthalmologyWet Age-Related Macular Degeneration (wet AMD)Diabetic Macular Edema (DME) KSI-101KSI-101 / IL-6 / VEGF / Bispecific Protein / OphthalmologyMacular Edema Secondary to Inflammation (MESI) 3assets mivocabtagene autoleucelKYV-101 / CD19 / Autologous CAR T-cell therapy / Autoimmune DiseasesStiff Person Syndrome (SPS)Phase 2Completed (Preparing BLA)USGeneralized Myasthenia Gravis (gMG)Phase 3OngoingUSLupus Nephritis (LN)Phase 1/2OngoingUSGermany KYV-102KYV-102 / CD19 / Autologous CAR T-cell therapy / Autoimmune DiseasesAutoimmune DiseasesPhase 1IND ActiveUS KYV-201KYV-201 / CD19 / Allogeneic CAR T-cell therapy / Autoimmune DiseasesAutoimmune DiseasesPreclinicalActiveUS 3assets SotagliflozinINPEFA / ZYNQUISTA / SGLT1 / SGLT2 / Small Molecule / CardiometabolicHeart FailureApprovedactiveUnited StatesHypertrophic Cardiomyopathy (HCM)Phase 3activeGlobalType 1 Diabetes (T1D)RegistrationactiveUnited States PilavapadinLX9211 / AAK1 / Small Molecule / Pain / NeurologyDiabetic Peripheral Neuropathic Pain (DPNP)Phase 2bactiveUnited StatesPostherpetic Neuralgia (PHN)Phase 2inactiveUnited States LX9851LX9851 / ACSL5 / Small Molecule / MetabolismObesity / Weight ManagementPhase 1activeGlobal 3assets 3assets ZidesamtinibNVL-520 NeladalkibNVL-655 3assets LicaminlimabOCS-02 PrivosegtorOCS-05 3assets 3assets 3assets 3assets D-PLEX100D-PLEX100 / Bacterial Ribosome / Small Molecule Formulation / Infectious Diseases / Surgical Site CarePrevention of surgical site infections (SSIs) following abdominal colorectal surgeryPhase 3OngoingUnited StatesEuropeIsrael PP03APP03A / GLP-1 Receptor / Peptide Formulation / Metabolic DiseaseObesity and Type 2 DiabetesPreclinicalOngoing PP04APP04A / OncoPLEX / STING / Small Molecule Formulation / OncologySolid TumorsPreclinicalOngoing 3assets QRX003QRX003 / Serine protease inhibitor / Small molecule / DermatologyNetherton SyndromePhase 3OngoingUnited StatesEuropeMiddle EastPeeling Skin SyndromePhase 2OngoingNew Zealand Topical rapamycinQRX009 / mTOR / Small molecule / DermatologyMicrocystic Lymphatic MalformationsPreclinicalOngoingGlobalVenous MalformationsPreclinicalOngoingGlobalAngiofibromaPreclinicalOngoingGlobal QRX008QRX008 / VLA-4 / VCAM-1 inhibitor / Small molecule / DermatologySclerodermaPreclinicalOngoingGlobal 3assets RAP-219RAP-219 / TARP8 AMPAR / Small molecule / Neurology/PsychiatryFocal onset seizuresPrimary generalized tonic-clonic seizuresBipolar mania 64 nAChR Agonist64 nAChR / Small molecule / NeurologyChronic painMigraine 910 nAChR Modulator910 nAChR / Small molecule / Hearing/VestibularHearing disordersVestibular disorders 3assets PC111PC111 / sFasL (soluble Fas Ligand) / Monoclonal Antibody / Immunology / DermatologyPemphigusPreclinicalActiveGlobalStevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN)PreclinicalActiveGlobal Intradermal IL-17A/F NanoAbIL-17A / IL-17F / VHH Antibody Fragment (NanoAb) / Immunology / DermatologyMild-to-moderate plaque psoriasisPreclinicalActiveGlobal Systemic Bi-Specific IL-17 NanoAbIL-17A / IL-17F and secondary proprietary target / Bi-specific VHH Antibody Fragment (NanoAb) / Immunology / DermatologyModerate-to-severe plaque psoriasisPreclinicalActiveGlobalPsoriatic arthritisPreclinicalActiveGlobal 3assets DenifanstatASC40 / FASN / Small molecule / Metabolic disease, Dermatology, OncologyMASH (F2/F3)Phase 3ActiveModerate to severe acnePhase 3ActiveRecurrent glioblastoma (GBM)Phase 3Active TVB-3567FASN / Small molecule / Dermatology, OncologyAcnePhase 1ActiveSolid tumorsPreclinicalActive FASNi TopicalFASN / Small molecule / DermatologyAcnePreclinicalActive 3assets 3assets lotilaner ophthalmic solution 0.25%TP-03 / XDEMVY / Small molecule / Eye CareDemodex blepharitisMeibomian Gland Disease lotilaner ophthalmic gelTP-04 / Small molecule / Dermatology / Eye CareRosaceaOcular rosacea lotilaner oral tabletTP-05 / Small molecule / Infectious Disease PreventionLyme disease preventionCommunity reduction of malaria 3assets TX45TX-000045 / RXFP1 / Fc-relaxin fusion protein / CardiopulmonaryPH-HFpEF (Group 2 Pulmonary Hypertension)PH-HFrEF (Group 2 Pulmonary Hypertension)PH-ILD (Group 3 Pulmonary Hypertension) TX2100TX002100 / GPCR / Biotherapeutic / GPCR Antagonist / Hematology / Rare DiseasesHereditary Hemorrhagic Telangiectasia (HHT) Fibrosis ProgramGPCR / Bispecific GPCR Antagonist / FibrosisFibrosis 3assets ublituximabTG-1101 / BRIUMVI / CD20 / Monoclonal Antibody / Autoimmune DiseasesRelapsing Multiple Sclerosis (RMS) ublituximab subcutaneousCD20 / Monoclonal Antibody / Autoimmune DiseasesRelapsing Multiple Sclerosis (RMS) azercabtagene zapreleucelazer-cel / CD19 / Allogeneic CAR-T Cell Therapy / Autoimmune DiseasesProgressive Multiple Sclerosis (PMS)Autoimmune Diseases 3assets Intranasal ForalumabTZLS-401 / CD3 epsilon / Monoclonal Antibody / Neurology/ImmunologyNon-Active Secondary Progressive Multiple Sclerosis (SPMS)Multiple System Atrophy (MSA)Mild Alzheimer's Disease Anti IL-6R mAbTZLS-501 / IL-6R / Monoclonal Antibody / Immunology MilciclibTZLS-201 / CDKs / Small Molecule / OncologyNSCLC with pan KRAS-positive mutations 3assets TN-201TN-201 / MYBPC3 / AAV-based gene therapy / CardiovascularMYBPC3-associated Hypertrophic Cardiomyopathy (HCM) TN-401TN-401 / PKP2 / AAV9-based gene therapy / CardiovascularPKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) TN-301TN-301 / HDAC6 / Small Molecule / Cardiometabolic / NeuromuscularHeart Failure with preserved Ejection Fraction (HFpEF)Duchenne Muscular Dystrophy (DMD) 3assets sparsentanFILSPARI pegtibatinaseTVT-058 tioproninThiola / Thiola EC 3assets dabogratinibTYRA-300 / FGFR3 / Small molecule / Oncology / Skeletal DysplasiaMetastatic Urothelial Cancer (mUC)Non-Muscle Invasive Bladder Cancer (IR NMIBC)Achondroplasia TYRA-200TYRA-200 / FGFR1/2/3 / Small molecule / OncologyIntrahepatic CholangiocarcinomaAdvanced Solid Tumors TYRA-430TYRA-430 / FGFR4/3 / Small molecule / OncologyHepatocellular Carcinoma (HCC)Advanced Solid Tumors 3assets AtaciceptVT-001 / BAFF and APRIL / Recombinant Fusion Protein / Immunology / NephrologyIgA Nephropathy (IgAN)BLA SubmittedPriority Review (PDUFA July 2026)USGlobalLupus NephritisPhase 2OngoingGlobalFocal Segmental Glomerulosclerosis (FSGS)Phase 2OngoingGlobal MAU868MAU868 / BK Virus / Monoclonal Antibody / Infectious Disease / TransplantationBK Viremia in Kidney Transplant RecipientsPhase 2Evaluating for future developmentGlobal VT-109VT-109 / BAFF and APRIL / Fusion Protein / ImmunologyB Cell Mediated DiseasesPreclinicalActiveGlobal 3assets Avutometinib and DefactinibVS-6766 / VS-6063 / AVMAPKI FAKZYNJA CO-PACK / RAF/MEK and FAK / Small Molecule / OncologyKRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)ApprovedActiveUnited StatesRecurrent low-grade serous ovarian cancer (LGSOC)Phase 3ActiveGlobalMetastatic Pancreatic Cancer (PDAC)Phase 2ActiveGlobal AvutometinibVS-6766 / RAF/MEK / Small Molecule / OncologyBRAF, KRAS and NRAS-Mutant Solid TumorsPhase 1ActiveGlobal VS-7375GFH375 / KRAS G12D / Small Molecule / OncologyKRAS G12D-Mutated Solid TumorsPhase 1/Phase 2ActiveUnited StatesChina 3assets tibulizumabZB-106 / IL-17A and BAFF / Bispecific dual-antagonist antibody / Autoimmune and Inflammatory DiseasesHidradenitis suppurativaSystemic sclerosis crebankitugZB-168 / IL-7R / Monoclonal antibody / Autoimmune and Inflammatory DiseasesAutoimmune and inflammatory conditions torudokimabZB-880 / IL-33 / Monoclonal antibody / Autoimmune and Inflammatory DiseasesAutoimmune and inflammatory conditions 2assets 2assets ImdusiranAB-729

Storage duration critically impacts effectiveness - reconstituted GHK-Cu lasts only 21-28 days refrigerated due to copper oxidation concerns (shorter than most peptides), requiring strategic reconstitution of amounts usable within this window rather than preparing entire vials at once